FIGURE 1.
FIGURE 2.
Most common adverse reactions due to anlotinib treatment (incidence > 5%)
| Adverse reaction | All grades | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|---|
| n (%) | |||||
| Hand-foot syndrome | 15 (50.0) | 6 (20.0) | 5 (16.7) | 4 (13.3) | 0 |
| Hypertension | 12 (40.0) | 8 (26.7) | 3 (10.0) | 1 (3.3) | 0 |
| Oral mucositis | 11 (36.7) | 5 (16.7) | 2 (6.7) | 4 (13.3) | 0 |
| Hypothyroidism | 9 (30.0) | 7 (23.3) | 2 (6.7) | 0 | 0 |
| Fatigue | 8 (26.7) | 5 (16.7) | 3 (10.0) | 0 | 0 |
| Proteinuria | 5 (16.7) | 5 (16.7) | 0 | 0 | 0 |
| Positive urinary occult blood | 4 (13.3) | 4 (13.3) | 0 | 0 | 0 |
| Leukopenia | 3 (10.0) | 3 (10.0) | 0 | 0 | 0 |
| Nasal bleeding | 3 (10.0) | 0 | 0 | 3 (10.0) | 0 |
| Arthralgia | 2 (6.7) | 0 | 1 (3.3) | 1 (3.3) | 0 |
Baseline characteristics of 30 patients with recurrent or metastatic nasopharyngeal carcinoma treated with anlotinib monotherapy
| Characteristics | No. of patients (%) |
|---|---|
| Age (years) | |
| Median (55) | |
| Range (35–76) | |
| Sex | |
| Male | 25 (83.3) |
| Female | 5 (16.6) |
| ECOG status | |
| 0-1 | 24 (80.0) |
| 2 | 6 (20.0) |
| Disease stagea at diagnosis | |
| Stage II | 2 (6.7) |
| Stage III | 9 (30.0) |
| Stage IV | 19 (63.3) |
| Disease status when starting anlotinib therapy | |
| Local recurrence | 10 (33.3) |
| Metastatic diseaseb | 13 (43.3) |
| Both | 7 (23.3) |
| Metastatic sites | |
| Liver | 11 (36.7) |
| Lung | 10 (33.3) |
| Bone | 10 (33.3) |
| Distant lymph node | 8 (26.7) |
| Number of prior systemic therapy lines | |
| 0 | 8 (26.7) |
| 1 | 13 (43.3) |
| ≥ 2 | 9 (30.0) |
| Platinum-refractory diseasec | |
| Yes | 16 (53.3) |
| No | 14 (46.7) |
| Anlotinib starting dose | |
| 12 mg | 21 (70.0) |
| 10 mg | 9 (30.0) |
| RT for recurrent/metastatic lesions | |
| Yes | 3 (10.0) |
| No | 27 (90.0) |
| Surgical treatment for recurrent lesions | |
| Yes | 2 (6.7) |
| No | 28 (93.3) |
| Immunotherapy before anlotinib | |
| Yes | 3 (10.0) |
| No | 27 (90.0) |